hcvin3

HCV-IN-3 is a hepatitis C virus (HCV) NS3/4a protein inhibitor with an IC50 of 20 μM and a Kd of 29 μM.

HCV-IN-30 is an HCV NS5A replication complex inhibitor (IC50s: 901 and 102 nM for genotypes 1a and 1b replicons).

HCV-IN-38 is a selective, potent, orally active hepatitis C virus (HCV) inhibitor with an EC50 value of 15 nM and an SI value of 431. HCV-IN-38 has a good safety profile and oral pharmacokinetics, exhibiting high anti-HCV activity and low cytotoxic effects.

HCV-IN-35 is a potent inhibitor of HCV and shows potential for infectious disease research.

HCV-IN-36 is an orally active HCV entry inhibitor that exhibits good antiviral activity (EC50: 0.016 μM, CC50 (half of the maximum cytotoxic concentration): 8.78 μM).

HCV-IN-33 [Compound (S)-3i] is an inhibitor of HCV entry.

HCV-IN-34 is an orally active HCV entry inhibitor. HCV-IN-35 exhibits good antiviral efficacy (EC50: 0.010 μM, CC50 (half of the maximum cytotoxic concentration): 7.50 μM).

HCV-IN-37 is a potent inhibitor of HCV. HCV-IN-37 is able to persist in rat plasma after oral administration to rats at a single dose of 15 mg/kg. The high potency of the active derivative HCV-IN-37 is mainly driven by the inhibition of the entry phase of the virus.

HCV-IN-31 is a HCV inhibitor with an EC50/EC95 of 15.7 μM.